Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer

医学 内科学 肺癌 化疗 中期分析 肿瘤科 阶段(地层学) 不利影响 随机对照试验 外科 古生物学 生物
作者
Shun Lü,Wei Zhang,Lin Wu,Wenxiang Wang,Peng Zhang,Neotorch Investigators,Wentao Fang,Wenqun Xing,Qixun Chen,Lin Yang,Jiandong Mei,Lijie Tan,Xiaohong Sun,Shidong Xu,Xiaohua Hu,Guohua Yu,Dongliang Yu,Nong Yang,Yuping Chen,Jinlu Shan
出处
期刊:JAMA [American Medical Association]
卷期号:331 (3): 201-201 被引量:397
标识
DOI:10.1001/jama.2023.24735
摘要

Importance: Adjuvant and neoadjuvant immunotherapy have improved clinical outcomes for patients with early-stage non-small cell lung cancer (NSCLC). However, the optimal combination of checkpoint inhibition with chemotherapy remains unknown. Objective: To determine whether toripalimab in combination with platinum-based chemotherapy will improve event-free survival and major pathological response in patients with stage II or III resectable NSCLC compared with chemotherapy alone. Design, Setting, and Participants: This randomized clinical trial enrolled patients with stage II or III resectable NSCLC (without EGFR or ALK alterations for nonsquamous NSCLC) from March 12, 2020, to June 19, 2023, at 50 participating hospitals in China. The data cutoff date for this interim analysis was November 30, 2022. Interventions: Patients were randomized in a 1:1 ratio to receive 240 mg of toripalimab or placebo once every 3 weeks combined with platinum-based chemotherapy for 3 cycles before surgery and 1 cycle after surgery, followed by toripalimab only (240 mg) or placebo once every 3 weeks for up to 13 cycles. Main Outcomes and Measures: The primary outcomes were event-free survival (assessed by the investigators) and the major pathological response rate (assessed by blinded, independent pathological review). The secondary outcomes included the pathological complete response rate (assessed by blinded, independent pathological review) and adverse events. Results: Of the 501 patients randomized, 404 had stage III NSCLC (202 in the toripalimab + chemotherapy group and 202 in the placebo + chemotherapy group) and 97 had stage II NSCLC and were excluded from this interim analysis. The median age was 62 years (IQR, 56-65 years), 92% of patients were male, and the median follow-up was 18.3 months (IQR, 12.7-22.5 months). For the primary outcome of event-free survival, the median length was not estimable (95% CI, 24.4 months-not estimable) in the toripalimab group compared with 15.1 months (95% CI, 10.6-21.9 months) in the placebo group (hazard ratio, 0.40 [95% CI, 0.28-0.57], P < .001). The major pathological response rate (another primary outcome) was 48.5% (95% CI, 41.4%-55.6%) in the toripalimab group compared with 8.4% (95% CI, 5.0%-13.1%) in the placebo group (between-group difference, 40.2% [95% CI, 32.2%-48.1%], P < .001). The pathological complete response rate (secondary outcome) was 24.8% (95% CI, 19.0%-31.3%) in the toripalimab group compared with 1.0% (95% CI, 0.1%-3.5%) in the placebo group (between-group difference, 23.7% [95% CI, 17.6%-29.8%]). The incidence of immune-related adverse events occurred more frequently in the toripalimab group. No unexpected treatment-related toxic effects were identified. The incidence of grade 3 or higher adverse events, fatal adverse events, and adverse events leading to discontinuation of treatment were comparable between the groups. Conclusions and Relevance: The addition of toripalimab to perioperative chemotherapy led to a significant improvement in event-free survival for patients with resectable stage III NSCLC and this treatment strategy had a manageable safety profile. Trial Registration: ClinicalTrials.gov Identifier: NCT04158440.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
molihuakai的应助被Hyy采纳,获得10
刚刚
细心鲂发布了新的文献求助10
1秒前
1秒前
2秒前
领导范儿的应助被X老师采纳,获得10
2秒前
oooo完成签到,获得积分10
2秒前
penicillin完成签到 ,获得积分10
2秒前
Jasper的应助被科研小白采纳,获得10
3秒前
牧百川发布了新的文献求助10
3秒前
敏家发布了新的文献求助10
3秒前
4秒前
张天泽完成签到,获得积分10
5秒前
5秒前
ZHIWAI完成签到,获得积分10
5秒前
6秒前
喵总完成签到,获得积分10
6秒前
6秒前
heeh发布了新的文献求助10
6秒前
缓慢念波发布了新的文献求助10
6秒前
7秒前
8秒前
身处人海完成签到,获得积分10
9秒前
影子子子完成签到,获得积分10
9秒前
净心完成签到,获得积分10
9秒前
我是老大的应助被风吹麦浪采纳,获得10
9秒前
仰泳鲫鱼完成签到,获得积分10
10秒前
11秒前
Orange的应助被nhzz2023采纳,获得10
11秒前
和谐青文完成签到 ,获得积分10
11秒前
太阳没回头完成签到,获得积分10
13秒前
molihuakai的应助被机智铃铛采纳,获得10
14秒前
jackzzs完成签到,获得积分10
15秒前
俊逸吐司发布了新的文献求助10
15秒前
lemon发布了新的文献求助10
15秒前
15秒前
牧百川发布了新的文献求助10
15秒前
啵啵虎完成签到,获得积分10
16秒前
weimei发布了新的文献求助10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183667
求助须知:如何正确求助?哪些是违规求助? 9572953
关于积分的说明 21828185
捐赠科研通 7780853
什么是DOI,文献DOI怎么找? 3434031
关于科研通互助平台的介绍 2558251
邀请新用户注册赠送积分活动 2480500